FITC-Linked Polyclonal Antibody to Osteonectin (ON) Homo sapiens (Human) Labelled antibody

SPARC; BM-40; Secreted Protein,Acidic,Cysteine-Rich; Basement-membrane protein 40; Secreted protein acidic and rich in cysteine

Add to Cart Distributors
Overview
Properties
  • SourceAntibody labeling
  • Ig Type IgG, Potency n/a
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelFITC
  • Original Antibody PAA791Hu01-Polyclonal Antibody to Osteonectin (ON)
  • Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
  • TraitsLiquid, Concentration 500µg/mL
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • FITC-Linked Polyclonal Antibody to Osteonectin (ON) Packages (Simulation)
  • FITC-Linked Polyclonal Antibody to Osteonectin (ON) Packages (Simulation)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a rabbit polyclonal antibody raised against ON. It has been selected for its ability to recognize ON in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.5-2µg/mL
Immunohistochemistry: 5-20µg/mL
Immunocytochemistry: 5-20µg/mL
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • Growth hormone replacement therapy regulates microRNA-29a and targets involved in insulin resistancePubMed: 26199111
  • Effect of resistance ladder training on SPARC expression in skeletal muscle of hindlimb immobilized ratsPubMed: 26467437
  • An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic CancerPubMed: 26266370
  • A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesotheliomaPubmed:26889976
  • Associations between FGF21, osteonectin and bone turnover markers in type 2 diabetic patients with albuminuria.pubmed:27916484
  • Association of Bone Metabolic Markers With Diabetic Retinopathy and Diabetic Macular Edema in Elderly Chinese Individuals With Type 2 Diabetes Mellituspubmed:29078839
  • Testican 1 (SPOCK1) and protein tyrosine phosphatase, receptor type S (PTPRS) show significant increase in saliva of tobacco users with oral cancerDoi: 10.1177/2057178X18800534
  • Osteoconductive potential of PLGA/bioglass composite biomaterials

Recommend products